Gracell Biotechnologies Inc. (GRCL) |
|
4.99 -0.42 (-7.76%)
|
06-26 22:50 |
|
Open: |
5.42 |
Pre. Close: |
5.41 |
|
High:
|
5.4331 |
Low:
|
4.85 |
|
Volume:
|
121,481 |
Market Cap:
|
337(M) |
|
|
|
|
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.44 - 5.46 |
5.46 - 5.49 |
|
Low:
|
4.79 - 4.82 |
4.82 - 4.84 |
|
Close:
|
4.95 - 4.99 |
4.99 - 5.03 |
|
Technical analysis |
as of: 2022-06-24 4:40:22 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 6.64 One year: 7.76 |
| Support: |
Support1: 3.79 Support2: 2.62 |
| Resistance: |
Resistance1: 5.69 Resistance2: 6.64 |
| Pivot: |
3.96  |
| Moving Average: |
MA(5): 5 MA(20): 3.72
MA(100): 2.94 MA(250): 7.02 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 84.4 %D(3): 86.4 |
| RSI: |
RSI(14): 70.7 |
| 52-week: |
High: 15 Low: 1.67 |
| Average Vol(K): |
3-Month: 149 (K) 10-Days: 174 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GRCL ] has closed below upper band by 18.9%. Bollinger Bands are 164.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Mon, 13 Jun 2022
Should You Accumulate Gracell Biotechnologies Inc (GRCL) Stock Monday Morning? - InvestorsObserver
Thu, 09 Jun 2022
Gracell Biotechnologies Inc. (NASDAQ:GRCL) Forecasted to Post FY2023 Earnings of ($0.28) Per Share - MarketBeat
Wed, 01 Jun 2022
Gracell Biotechnologies (NASDAQ:GRCL) Now Covered by Cantor Fitzgerald - MarketBeat
Wed, 01 Jun 2022
Gracell Biotechnologies (GRCL) Stock Price: Why It Increased Over 14% Today - Pulse 2.0
Fri, 27 May 2022
Gracell Biotechnologies (NASDAQ:GRCL) Price Target Cut to $10.00 by Analysts at Piper Sandler - MarketBeat
Mon, 23 May 2022
Is Gracell Biotechnologies Inc (GRCL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
68 (M) |
|
% Held by Insiders
|
2.049e+007 (%) |
|
% Held by Institutions
|
7.7 (%) |
|
Shares Short
|
634 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.7542e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-143 |
|
Return on Assets (ttm)
|
745.3 |
|
Return on Equity (ttm)
|
-15.3 |
|
Qtrly Rev. Growth
|
366000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-5.69 |
|
Qtrly Earnings Growth
|
-1.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
920.28 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
578610 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
